Daiichi Sankyo

New Capabilities

Originator of trastuzumab deruxtecan; holder of the FDA approval

The U.S. Food and Drug Administration (FDA) cleared AstraZeneca and Daiichi Sankyo's Enhertu for two new uses in early-stage HER2-positive breast cancer in May 2026. The drug, already a standard for advanced disease, now enters the window where the goal is cure, not control.

Updated May 18